RSV: National Report Card

A national data supplier provided palivizumab claims for Medicaid and commercial health plans across the nation from January 2019 through December 2019.

  • Health plans deny 40% of palivizumab prescriptions for premature infants born between 29 and 36 weeks gestation.
  • One in every four prescriptions is denied for infants who should qualify for coverage under standard insurance policies.

Read Report Card


Categorized in: